Abstract

This study aimed to determine if short-term exposure to particulate matter (PM2.5) and ozone (O3) is associated with increased symptoms or lung function decline in fibrotic sarcoidosis. Sixteen patients with fibrotic sarcoidosis complicated by frequent exacerbations completed pulmonary function testing and questionnaires every three months for one year. We compared 7-, 10-, and 14-day average levels of PM2.5 and O3 estimated at patient residences to spirometry (forced expiratory volume in 1 s (FEV1), to forced vital capacity (FVC), episodes of FEV1 decline > 10%) and questionnaire outcomes (Leicester cough questionnaire (LCQ), Saint George Respiratory Questionnaire (SGRQ), and King’s Sarcoidosis Questionnaire (KSQ)) using generalized linear mixed effect models. PM2.5 level averaged over 14 days was associated with lower KSQ general health status (score change −6.60 per interquartile range (IQR) PM2.5 increase). PM2.5 level averaged over 10 and 14 days was associated with lower KSQ lung specific health status (score change −6.93 and −6.91, respectively). PM2.5 levels were not associated with FEV1, FVC, episodes of FEV1 decline > 10%, or respiratory symptoms measured by SGRQ or LCQ. Ozone exposure was not associated with any health outcomes. In this small cohort of patients with fibrotic sarcoidosis, PM2.5 exposure was associated with increased severity of respiratory and quality of life symptoms.

Highlights

  • Chronic sarcoidosis progresses to fibrotic disease in approximately 10–20% of patients [1].Fibrotic disease is characterized by a progression of chronic inflammation to fibrotic transformation, and may include upper and middle lung predominant findings of traction bronchiectasis, bronchial distortion, linear opacities, fibrotic masses, honeycombing, or cysts [1,2].Int

  • We aimed to evaluate if short-term exposure to ozone and fine particulate matter (PM2.5 ) is associated with increased symptoms or lung function decline in an exploratory study of a small cohort of patients with fibrotic sarcoidosis

  • Short-term ozone exposure was not associated with respiratory symptoms measured by Saint George Respiratory Questionnaire (SGRQ), LCG, or King’s Sarcoidosis Questionnaire (KSQ)

Read more

Summary

Introduction

Chronic sarcoidosis progresses to fibrotic disease in approximately 10–20% of patients [1].Fibrotic disease is characterized by a progression of chronic inflammation to fibrotic transformation, and may include upper and middle lung predominant findings of traction bronchiectasis, bronchial distortion, linear opacities, fibrotic masses, honeycombing, or cysts [1,2].Int. Public Health 2018, 15, 1077; doi:10.3390/ijerph15061077 www.mdpi.com/journal/ijerph

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.